# Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

> **NCT04075513** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 343 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine, 300 U/ml
- **DRUG:** Insulin degludec, 100U/ml
- **DRUG:** Background therapy: Rapid acting insulin analogs

## Key facts

- **NCT ID:** NCT04075513
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-09
- **Primary completion:** 2021-09-16
- **Final completion:** 2021-09-16
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04075513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04075513, "Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04075513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*